A trial in Brazil showed CoronaVac to be 50.7 per cent effective at stopping symptomatic Covid-19. Photo: EPA-EFE
A trial in Brazil showed CoronaVac to be 50.7 per cent effective at stopping symptomatic Covid-19. Photo: EPA-EFE

Sinovac shot cuts risk of symptomatic Covid-19 in half, study says

  • Primary efficacy rate found to be 50.7 per cent, according to results of final-stage trial in Brazil
  • Separate study, also in Brazil, finds product to be almost 50 per cent effective at curbing the infection risk of the P1 variant

A trial in Brazil showed CoronaVac to be 50.7 per cent effective at stopping symptomatic Covid-19. Photo: EPA-EFE
A trial in Brazil showed CoronaVac to be 50.7 per cent effective at stopping symptomatic Covid-19. Photo: EPA-EFE
READ FULL ARTICLE